Phathom launches VOQUEZNA for erosive GERD; H. pylori regimens expected mid-Dec.

Phathom Pharmaceuticals, Inc.

VOQUEZNA (vonoprazan) now available in 30-count bottles for erosive GERD treatment and heartburn relief.
Phase 3 trial: 93% healing rate at Week 8 with VOQUEZNA 20mg vs 85% for lansoprazole 30mg.
VOQUEZNA 10mg superior to lansoprazole 15mg at maintaining healing at 6 months (79% vs 72%).
No mealtime dosing required; prescriptions fillable at major retail pharmacies and via BlinkRx.
VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori expected commercially by mid-December 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.